First AD

Second AD

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Translating Evidence to Practice to Improve Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Peer Exchange

Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.

Treatment Options for Patients with R/R DLBCL

Front-Line Treatment Options for Patients with DLBCL

An Overview of R/R DLBCL

L-MIND: Review of Long-Term Analyses Data

Role of CAR T-cell Therapy in Patients with R/R DLBCL

Eligibility Criteria for CAR T-Cell Therapy in R/R DLBCL

ZUMA-7: Clinical Implications

Sequencing Therapies in Patients with R/R DLBCL

Potential Role of CAR T-cell Therapy in the Front-line Setting for Patients with R/R DLBCL

Future of R/R DLBCL